FDA warned Sonesta Medical AB that its radiographic and cystometric tables violated device quality system rules.
What happened
FDA inspected Sonesta Medical AB's Solna, Sweden, facility from June 5 to June 7, 2023. FDA found inadequate procedures and records for supplier evaluation, complaint handling, design controls, and document control, and said the company's responses were incomplete.
What FDA found
The company's supplier-evaluation procedure did not say how often or how much to control suppliers, contractors, and consultants, and it had not evaluated its repair servicer or QA/RA consultant.
21 CFR 820.50(a)Its complaint procedure did not require deciding whether complaints needed Medical Device Reporting review, and complaint records lacked investigation dates and results and unique device identifier (UDI) codes.
21 CFR 820.198(a)It had no procedure for resolving incomplete, ambiguous, or conflicting design requirements.
21 CFR 820.30(c)Its design validation procedure did not require testing on initial production units or under actual or simulated use conditions.
21 CFR 820.30(g)It had no procedure to control design changes, including describing changes, deciding on verification or validation, assessing risk impact, or checking new regulatory requirements.
21 CFR 820.30(i)Its document-control procedure did not require signed and dated approval of quality documents, and many procedures lacked unique document numbers.
21 CFR 820.40
What FDA wants
FDA asks Sonesta Medical AB to respond in writing within 15 business days with the specific corrections and corrective actions, including documentation and a timetable for any actions not finished. It also asks for retrospective reviews and English translations of non-English documents.
Who should pay attention
- medical device manufacturers using contract servicers or consultants
- companies that buy or distribute radiographic or cystometric tables
- quality teams managing supplier, complaint, design, and document controls
This is a summary. Read the original letter on fda.gov.